Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with

Status Not yet recruiting

Clinical Trial Summary

Surgical lymph node dissection is the key to advanced gastric cancer. In recent years, after the overall implementation of standard D2 dissection, lymph node dissection for gastric cancer began to explore the direction of D1+ again. Current clinical studies of gastric cancer lymph node dissection based on intraoperative fluorescence navigation show that non-tumor specific lymph node fluorescence navigation surgery can only increase the total number of lymph nodes detected and ensure the completion of the dissection but not the accuracy. The sensitivity and specificity of the tracer metastatic lymph nodes are 56.3% (410/728), respectively. Specificity 46.1% (2669/5785). Tumor specific tracing of positive lymph nodes is the key to achieve accurate lymph node dissection for gastric cancer. Although tumor specific tracers are developing rapidly and related clinical studies are gradually being carried out, there are few reports on specific clinical studies on lymph node metastasis, suggesting that lymph node tracing is still a difficult problem. Previous basic studies have suggested that integrins play an important molecular biological role in the process of tumor lymph node metastasis. In the early stage, 99mTc3PRGD2 SPECT-CT showed good lymph node imaging effect in lung cancer and breast cancer, and 99mTc-oncoFAPI PET-CT also showed good lymph node imaging effect in gastric cancer. Therefore, this study aims to explore the application prospect of 99mTc3PRGD2 and other probes in molecular imaging of gastric cancer metastatic lymph nodes and guidance of lymph node dissection and tracer, so as to accumulate preliminary clinical data for exploring corresponding fluorescent probes for intraoperative tracer of gastric cancer lymph nodes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06435741
Study type	Interventional
Source	Peking University Cancer Hospital & Institute
Contact	yongning Jia
Phone	0086-10-88196606
Email	yongningjia@bjmu.edu.cn
Status	Not yet recruiting
Phase	N/A
Start date	June 6, 2024
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03313700` - Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer	N/A
Recruiting	`NCT05645198` - The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy	Phase 4
Completed	`NCT03549494` - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction	Phase 2
Completed	`NCT00935779` - Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer	N/A
Completed	`NCT00144378` - Irinotecan Versus Only Best Supportive Care for Gastric Cancer	Phase 3
Completed	`NCT00290966` - Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer	Phase 2/Phase 3
Recruiting	`NCT03348150` - Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.	Phase 3
Not yet recruiting	`NCT06085677` - The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Recruiting	`NCT02969122` - Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor	N/A
Completed	`NCT01482299` - RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression	Phase 2
Active, not recruiting	`NCT03760822` - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients	Phase 2
Recruiting	`NCT00509964` - Second-Line Irinotecan vs. ILF for AGC	Phase 2
Completed	`NCT04889859` - Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy	N/A
Completed	`NCT03071237` - The Origin of Infrapyloric Artery
Recruiting	`NCT05184803` - A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer	Phase 2
Completed	`NCT05714878` - Multimodal Prehabilitation for Resectable Gastric Cancer	N/A
Completed	`NCT00142038` - Docetaxel and Capecitabine in Advanced Gastric Cancer	Phase 2
Not yet recruiting	`NCT04056260` - ICG-NIR Guided Lymph Node Dissection in Gastric Cancer	N/A
Recruiting	`NCT03065257` - Endoscopic Resection Multicenter Registry	N/A
Recruiting	`NCT04744649` - Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with 99mTc-3PRGD2 Probe.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms